FDA closes Eprex investigation
FDA closes investigation of J&J's Manati, Puerto Rico facility, without any findings, J&J says. The investigation was prompted by a "whistleblower" suit in which a former employee alleged the company pressured him to falsify documents relating to the manufacture of Eprex (epoetin alfa), marketed in U.S. as Procrit (1"The Pink Sheet" July 22, 2002, p. 11). The suit was dismissed by San Juan Federal District Court in June at plaintiff's request, J&J says. The dismissal precludes the employee from bringing claims again...
You may also be interested in...
Johnson & Johnson is recommending intravenous administration of Eprex (epoetin alfa) over subcutaneous administration in chronic renal failure patients in order to decrease the incidence of pure red blood cell aplasia in a July 17 "Dear Doctor" letter to physicians in the EU
Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances
Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.
Class action complaints filed in 2020 against food, dietary supplement and beverage firms should pass 2019’s total as COVID-19 has not slowed litigants but has given plaintiffs’ council more time out of court to shop for new cases.